{"id":"NCT00226655","sponsor":"Celtic Pharma Development Services","briefTitle":"An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies","officialTitle":"An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2009-03","completion":"2009-04","firstPosted":"2005-09-27","resultsPosted":"2012-08-31","lastUpdate":"2012-08-31"},"enrollment":112,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Brain Edema","Brain Tumor"],"interventions":[{"type":"DRUG","name":"hCRF [XERECEPT (corticorelin acetate injection)]","otherNames":["hCRF, XERECEPT (corticorelin acetate injection)"]}],"arms":[{"label":"I","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPTÂ®, in patients requiring dexamethasone (Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other designated studies, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods.","primaryOutcome":{"measure":"Long Term Safety and Tolerability of hCRF","timeFrame":"Prospective","effectByArm":[{"arm":"hCRF","deltaMin":111,"sd":4.5}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":32,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":72,"n":112},"commonTop":["Neoplasm progression","Convulsion","Headache","Flushing","Nausea"]}}